Outcome of Board Meeting

August 22, 2026 To, To, Listing / Compliance Department Listing / Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, "Exchange Plaza", Plot No. C/1, Dalal Street, Mumbai - 400 001 G Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 Scrip Code: 543210 Symbol: AARTISURF Dear Sir / Madam, Sub: Outcome of the Board Meeting held on Saturday, August 22, 2026 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held today, i.e., Saturday, August 22, 2026, inter alia, considered and approved the following: 1. Re-appointment of Mr. Nikhil P. Desai (DIN: 01660649) as CEO & Managing Director of the Company, for a period of 5 (Five) years with effect from August 20, 2027 based on the recommendation of Nomination and Remuneration Committee and subject to the further approval of the Shareholders of the Company at the ensuing Annual General Meeting. 2. Re-appointment of Mr. Santosh M. Kakade (DIN: 08505234) as an Executive Director of the Company, for a period of 5 (Five) years with effect from August 20, 2027, based on the recommendation of Nomination and Remuneration Committee and subject to the further approval of the Shareholders of the Company at the ensuing Annual General Meeting. The requisite details relating to the re-appointments of Mr. Nikhil P. Desai and Mr. Santosh M. Kakade, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Master Circular dated January 30, 2026, are annexed hereto as Annexure A. 3. Appointment of Prof. Vandana B. Patravale (DIN: 09200693), as an Additional Director in the category of Non-Executive Independent Director of the Company for a period of 5 (Five) years with effect from August 22, 2026, based on the recommendation of Nomination and Remuneration Committee and subject to the further approval of the Shareholders of the Company at the ensuing Annual General Meeting. Further, the Independent Director fulfil the criteria of Independence as required under the provisions of the Companies Act, 2013 and the Rules framed thereunder and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The requisite details relating to the appointment, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Master Circular dated January 30, 2026, is annexed hereto as Annexure B. We hereby confirm that Mr. Nikhil P. Desai, Mr. Santosh M. Kakade and Prof. Vandana B. Patravale are not debarred from holding the office of Director by virtue of any order passed by SEBI or any other regulatory authority. 4. Alteration of the Main Object Clause of the Memorandum of Association to broaden the scope of the Company’s activities, subject to the approval of the shareholders at the ensuing Annual General Meeting. 5. Change in designation of Mrs. Kanika Rathore from Vice President – Business & Operations to President – Business & Operations, based on recommendation of Nomination and Remuneration Committee. The requisite details pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Master Circular dated January 30, 2026, is annexed hereto as Annexure C. The Meeting of the Board of Directors commenced at 03:30 p.m. and concluded at 04:50 p.m. The above information is also available on the website of the Company at www.aarti- surfactants.com Kindly take the above information on record. Thanking you, Yours faithfully, For Aarti Surfactants Limited Priyanka Chaurasia Company Secretary ICSI M. NO. A44258 Annexure A Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III and SEBI Master Circular dated January 30, 2026: Sr. Particulars Mr. Nikhil P. Desai Mr. Santosh M. Kakade 1 Reason for Changes Re-appointment of Mr. Nikhil P. Re-appointment of Mr. viz. appointment, Desai (DIN: 01660649) as CEO & Santosh M. Kakade (DIN: reappointment, Managing Director of the 08505234) as an Executive resignation, Company. Director of the company. removal, death or otherwise; 2 Date of Re-appointment for a Re-appointment for a appointment / re - consecutive term of 5 (five) consecutive term of 5 (five) appointment / years, effective from August 20, years, effective from August cessation (as 2027 to August 19, 2032, subject 20, 2027 to August 19, 2032, applicable) & term to the approval of the subject to the approval of the of appointment / re - Shareholders at the ensuing Shareholders at the ensuing appointment; Annual General Meeting. Annual General Meeting. Mr. Nikhil P. Desai shall Not Be Mr. Santosh M. Kakade shall liable to retire by rotation. be liable to retire by rotation. 3 Brief Profile (in case Mr. Nikhil P. Desai has over 20 Mr. Santosh M. Kakade has of appointment) years of rich experience across more than three decades of Information Technology, Project diverse experience in the Management, Technical Sales, fields of Plant Operations, Vendor Management, Team Process Development, Project Building, Process Improvement, Management, and General Business Strategy, Change Management. Management, Marketing and Product Development, with significant exposure to the pharmaceutical and chemical industries. 4 Disclosure of Mr. Nikhil P. Desai is the son of Mr. Santosh M. Kakade is not relationships Mr. Parimal H. Desai, Non- related to any Director of the between directors, Executive Director and Promoter Company. (in case of of the Company. appointment of a director) He also forms part of the Promoter Group of the Company. Annexure B Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III and SEBI Master Circular dated January 30, 2026: Sr. Particulars Prof. Vandana B. Patravale 1 Reason for Changes viz. Appointment of Prof. Vandana B. Patravale (DIN: appointment, reappointment, 09200693), as an Additional Director in the category resignation, removal, death or of a Non-Executive Independent Director otherwise; 2 Date of appointment / re - Appointment for a consecutive term of 5 (five) years, appointment / cessation (as effective from August 22, 2026, subject to the applicable) & term of approval of the Shareholders at the ensuing Annual appointment / re - appointment; General Meeting. 3 Brief Profile (in case of Prof. Vandana B. Patravale holds B. Pharm., M. appointment); Pharm. and Ph.D. (By Research, in Pharmaceutics) degrees from the University of Mumbai and is a Senior Professor of Pharmaceutics at the Institute of Chemical Technology (ICT), Mumbai, with over 35 years of academic, research and industry-oriented experience. Her areas of expertise include Pharmaceutics, Cosmeticology, Validation and Regulatory Affairs, and Advanced Pharmaceutics. She has supervised numerous research projects and has made significant contributions to the development of novel nanocarriers for cosmeceuticals and applications in areas of national relevance, including malaria, cancer and neurodegenerative disorders. She has an extensive portfolio of research publications and intellectual property, including several Indian and International patents. She has received several prestigious awards, including the Abdul Kalam National Innovation Fellowship, OPPI Woman Scientist Award, VASVIK Industrial Research Award and UAA-ICT Distinguished Alumnus Award etc. She has also played a significant role in the successful transfer of several Pharmaceutical Technologies. 4 Disclosure of relationships Prof. Vandana B. Patravale is not related to any between directors, (in case of Director of the Company. appointment of a director) Annexure C Disclosure of information pursuant to Regulation 30 [Showing first 8,000 characters — download PDF for full document]